Sotera Health Company SHC
Composite 56/100; the shares have moved about 31% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 38/100 — a moderate mark against it.
Growth ranks 70/100 — a moderate point in its favour. Momentum ranks 67/100 — a moderate point in its favour. Quality ranks 64/100 — a moderate point in its favour.
Valuation ranks 38/100 — a moderate mark against it. Balance-sheet strength ranks 45/100 — a slight mark against it.
What the company does Sotera Health (SHC) provides sterilization, lab testing, and advisory services for healthcare, operating through Sterigenics, Nordion, and Nelson Labs segments. Sterigenics offers terminal sterilization via gamma, ethylene oxide, and electron beam; Nordion supplies Cobalt-60 and gamma systems; Nelson Labs conducts microbiological and analytical testing.
Key financials SHC reports gross margins of 55.3%, operating margins of 31.3%, and net margins of 9.9%. ROE is 22.7%, ROA 8.5%, and ROCE 11.7%. Revenue grew 10.0% and EPS grew 175.4%. Debt/Equity is 3.65, net debt/EBITDA 3.49, and interest coverage is 2.37.
Stock health SIDERAVIA scores SHC as Average quality, richly valued (Overall 52.8). Quality (64.4) and Growth (64.9) are strong, but Strength (43.5) and Valuation (32.6) lag. Momentum is mixed: 3m +15.53%, 6m -2.30%, 12m +47.03%. RSI(14) is 56.60.
Price vs fair value SHC trades at a PREMIUM of 14.30% to our fair-value estimate of 15.29 and a discount of 14.53% to the analyst 12-month target of 20.44. - Premium vs fair value reflects high forward P/E of 17.51 and PEG of 0.13 (Valuation 32.6). - Discount to target cited by 9 analysts suggests perceived upside potential (analyst count 9.0). - Recent headline touts SHC as a "Strong Position" for portfolios (Insider Monkey 2026-07-28).
Looking forward Forward P/E of 17.51 and PEG of 0.13 imply growth is priced in, while Piotroski F-Score of 8/9 and current ratio of 2.82 suggest operational strength. Debt levels (Debt/Equity 3.65) remain a risk.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.